Download Chair, Department of Medical Oncology and Therapeutics Research

Chair, Department of Medical Oncology
and Therapeutics Research
Arthur & Rosalie Kaplan Chair in Medical Oncology
February 2015
Introduction and Overview
City of Hope (COH) seeks an medical oncologist with significant clinical practice
experience, a record of funded research and scholarly publication, and exceptional
leadership ability to become Chair of its Department of Medical Oncology and
Therapeutics Research. This is an exciting time at COH – the medical center has
strong momentum for growing its clinical service and research programs and has the
financial resources to continue the growth as well as program improvements at an
accelerated pace.
Driving the growth is a new leadership team that includes Robert Stone as President
and CEO and Steve Rosen, MD, who serves as COH’s Provost, Beckman Research
institute Director, and Cancer Center Director. Working with Alexandra Levine, MD,
MACP the COH’s Chief Medical Officer, this leadership team seeks a colleague as
department chair with whom they can work to help guide the institution to new levels of
excellence in cancer research, translational applications, and clinical care.
COH has the resources to support successful expansion, with impressive operating
results and an endowment of $1.8 billion, the proceeds of which will be used for hiring
additional clinicians and scientists, investing in translational and clinical research, and
expanding the care and clinical research network to an increasing number of community
practices aligned with COH. To enhance its already successful fundraising efforts, COH
has recently hired a new leader of development who has extensive experience in fund
raising for healthcare and research institutions.
Additional information about City of Hope can be found in Attachment 1 as well as at
www.cityofhope.org.
The Clinical Enterprise
Over 220 physicians are employed by COH Medical Group, an affiliate of the COH
Medical Foundation, providing services at the main campus in Duarte and at community
practices in greater Los Angeles.. The City of Hope Helford Clinical Research Hospital,
built in the last decade, has nearly 200 beds in a state-of-the-art building located in the
center of COH’s 120-acre main campus, with a total of 217 licensed beds.
.
COH has achieved regional and national prominence for several of its clinical programs.
Its surgeons have performed more than 8,000 robotic procedures (more than any other
institution in the nation), and COH has impressive market share in surgical cancer care
in southern California.
COH operates one of the nations largest, most successful bone marrow and stem cell
transplant programs. With an average daily census of 100 to 120 patients in the
hematology service, COH clinicians have carried out more than 12,000 bone marrow
2
and stem cell transplants, with significantly better outcomes than expected under
national standards. Thus, based on one year survival rates, COH has been given the
designation as an “overperforming” transplant center for the past 10 consecutive years,
by the Center for International Blood and Marrow Transplant Research (CIBMTR), the
only transplant center in the country to have achieved this level of excellence.
City of Hope is accredited for ACGME sponsored residency and fellowship programs,
with specific ACGME programs in Radiation Oncology, Surgery, Hematology/Oncology,
Hematopathology, and Diabetes/Endocrinology. Additional non-ACGME programs
include Bone Marrow Transplantation, Breast Surgery, and Psychology.
The Research Enterprise
Research at COH is conducted by over 90 principal investigators within its Beckman
Research Institute along with research conducted by scientists and clinician scientists in
COH’s clinical departments and divisions. The research enterprise encompasses wet
bench research in the laboratory, genetic cancer risk assessment, and survivorship
research, the ultimate goal being to swiftly move bold, innovative research concepts to
powerful new treatments. COH has an impressive history in running clinical trials and is
a national leader in translational research. Research funding at COH is approximately
$260 million annually.
Department of Medical Oncology and Therapeutics Research
The current department now includes over 40 oncologists, 20 physician extenders, and
approximately 18 administrative and support staff. An additional 140 professionals are
affiliated with the clinical care and research teams in medical oncology. The current
teams include: Women’s Cancer Program (breast and gynecology); Gastroenterology
Cancer Program; Genitourinary Cancer Program; Lung Cancer Program; Head and
Neck Cancer; Neuro Oncology; and Bone and Soft Tissue Sarcoma/Melanoma.
Over 43,000 ambulatory patient visits annually are provided by the Department’s clinical
staff in Duarte and community practices, and the Department has over 2,000 patients
enrolled in clinical trials.
The Opportunity
The new Chair, reporting to Dr. Levine, will lead the Department’s work to achieve the
following goals:

Expand the Department to support and enhance COH’s strategic plan, which
includes growing clinical operations and further developing clinical and translational
research. Of special interest will be strengthening and growing solid tumor
3
programs. Gastrointestinal, Women’s, Urologic, and Lung cancers will continue to be
a major areas of focus, augmented by other areas of interest, as identified by the
new chair in collaboration with COH’s leadership team and faculty. The goal will be
to develop one or several additional top tier programs that are recognized nationally
for their excellence.

Unite the Department’s current staff around the vision for clinical service growth and
expansion of research from bench to clinical science, and bring additional
community physicians into the COH Foundation to ensure access to the most
current therapeutic protocols and to maintain and enhance quality standards
throughout the region.

Recruit a new generation of physicians, clinical scientists, and research scientists,
who come from the world’s leading centers where they have experienced the highest
standards of excellence in research and clinical care.

Strengthen education and training programs to enhance COH’s national reputation
within the scientific and medical communities and to work with the Development
Office to grow philanthropy and COH’s visibility among patients and their families.

Work collaboratively with research and clinical faculty to further develop translational
research, to enhance COH’s reputation as a world-recognized center of excellence,
and to attract new levels of funding in basic, clinical, and translational research to
augment internal sources.
Education and Qualifications
Qualifications include:




MD degree or MD/PhD degrees
Promotion to the full professor rank (or senior associate professor rank) at a
major academic medical center, recognized for its excellence and
accomplishments.
Recognition for research accomplishments that reflect a deep understanding of
current trends in cancer treatment, including strategies for personalized
medicine; and
Five or more years of successful leadership experience.
The best candidates will also:

Have a participatory leadership style that models the values of service, initiative,
and collaboration and will build collaboration across COH by enlisting others in
pursuit of established goals and by delegating responsibility where appropriate;
4






Be eager to recruit and mentor junior faculty, and to work collaboratively with new
and existing faculty to promote their career development and through them, the
interests of the entire Department;
Be connected to leaders of other Comprehensive Cancer Centers and
international cancer organizations to enhance opportunities for collaboration and
clinical trials, and to identify outstanding candidates for faculty recruitment;
Demonstrate strong budgetary and operational skills;
Appropriately delegate responsibility to Department faculty;
Possess collegial, problem-solving style based on personal integrity and ethics,
professional confidence, and excellent relationship-management skills; and
Exhibit nuanced judgment and personal maturity.
Please send applications and nominations to the Brill Neumann team working on the
search:
Nicholas Brill and Jennifer McDonough
Brill Neumann Associates
[email protected]
Visit the City of Hope website http://www.cityofhope.org for additional information.
City of Hope is committed to equal opportunity and affirmative action.
5
Attachment 1
City of Hope
COH is a research, treatment, and educational center dedicated to the prevention,
treatment, and cure of cancer and diabetes. COH is designated as an NCI
Comprehensive Cancer Center and is a founding member of the National
Comprehensive Cancer Network. Located in Duarte California, COH is part of the Los
Angeles metropolitan area, and clinical reach is extended by 12 community practices
throughout Los Angeles and Riverside counties.
City of Hope includes the Beckman Research Institute (BRI), Helford Clinical Research
Hospital, the Medical Foundation (which operates the Brawerman Center for
Ambulatory Care and community practices), and the Finkel Women’s Health Center.
City of Hope is one of the nation’s 41 NCI-designated Comprehensive Cancer Centers
and is located in the Los Angeles metropolitan area. COH’s five NCI certified programs
are:
Molecular
Oncology;
Developmental
Cancer
Therapeutics;
Cancer
Immunotherapeutics; Hematologic Malignancies; and Cancer Control and Population
Sciences.
In the past decade, COH added major new lab space and a new inpatient hospital,
increased external research funding, formed a new medical foundation for the
physicians practicing at the institution, and achieved record setting fund raising. Within
the past two years the senior team at COH led the development of the current strategic
plan which positions COH for success in the very competitive southern California
marketplace.
Research at City of Hope
At City of Hope the clinical enterprise and Beckman conduct more clinical trials than
most cancer centers and it is a national leader in translational research, where ideas
continuously flow between scientists and clinicians.
Additionally, City of Hope has made substantial investments in buildings, equipment,
and people. City of Hope provides end-to-end translational research infrastructure
including three GMP facilities on the Duarte campus, and recently started a pipeline
development and commercialization program that utilizes both internal and external
advisors to aid in advancing the development of promising compounds. These assets
in total have led to a very promising pipeline of potential cancer and diabetes therapies.
In 2014 COH has created several new programs to focus research on pressing medical
issues – they include the Diabetes and Metabolism Research Institute, Hematologic
Malignancies and Stem Cell Transplantation Institute, and Alpha Clinic for Cell Therapy
and Innovation (ACT-I).
6
Duarte and Los Angeles County
COH is located in Duarte, California just 10 miles east of Pasadena and 22 miles
northeast of Los Angeles in the San Gabriel Valley. Duarte is close enough to Los
Angeles to take advantage of the benefits of city life and far enough to enjoy living in a
peaceful environment with majestic views of the San Gabriel Mountains. Duarte is also
located within close proximity to a variety of recreational activities so residents can
enjoy a day at the beach and skiing in the mountains in a single weekend.
7